Forecasting The Future: 5 Analyst Projections For Altimmune
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Altimmune (NASDAQ:ALT) with a range of price targets. The average 12-month price target is $18.6, with a high of $25.00 and a low of $12.00. Recent ratings show a slight decline in the average price target. Altimmune faces challenges in revenue growth, net margin, ROE, and ROA, but maintains a sound debt-to-equity ratio.
June 21, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Altimmune (NASDAQ:ALT) has received mixed ratings from analysts, with an average 12-month price target of $18.6. The company faces significant challenges in revenue growth, net margin, ROE, and ROA, but maintains a sound debt-to-equity ratio.
The mixed ratings and slight decline in the average price target indicate uncertainty among analysts about Altimmune's short-term performance. The company's financial challenges in revenue growth, net margin, ROE, and ROA further contribute to this uncertainty, although its sound debt-to-equity ratio is a positive aspect.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100